^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:anastrozole (Aromatase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/13/2018
    Excerpt:
    ARIMIDEX is an aromatase inhibitor indicated for:...First-line treatment of postmenopausal women with hormone receptorpositive or hormone receptor unknown locally advanced or metastatic breast cancer.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2 Negative Breast Cancer: Invasive Breast Cancer…SYSTEMIC THERAPY FOR ER - AND/OR PR - POSITIVE RECURRENT OR STAGE IV (M1) DISEASE…HER2-Negative and Postmenopausal or Premenopausal Receiving Ovarian Ablation or Suppression…Preferred Regimens...Seletive ER-down regulator(fulvestrant, category 1)+/-non-steroidal aromatase inhibhitor (anastrozole, letrozole) (category 1)
    Secondary therapy:
    anastrozole
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Clin Oncol
    Title:

    Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial

    Published date:
    04/20/2023
    Excerpt:
    This prospective, randomized, multicenter open-label phase III study assessed the effect of extending anastrozole treatment for an additional 5 years in postmenopausal patients who were disease-free after treatment with either 5 years of anastrozole alone or 2-3 years of tamoxifen followed by 2-3 years of anastrozole....The 5-year DFS rates were 91% (95% CI, 89 to 93) in the continue group and 86% (95% CI, 83 to 88) in the stop group (hazard ratio, 0.61; 95% CI, 0.46 to 0.82; P < .0010)....Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS.
    DOI:
    10.1200/JCO.22.00577
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Wiley Online Library
    Title:

    Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

    Excerpt:
    In patients whose tumors were ER and/or PgR+, anastrozole therapy provided a significant efficacy benefit over tamoxifen, the current treatment of choice in this patient group.
    DOI:
    10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

    Excerpt:
    ...HR-positive and HER2-positive breast cancer diagnosed pathologically....
    Trial ID:
    NCT05167643
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE THE ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCEREBC ATRA TRIAL L¿acido retinoico tutto-trans nel trattamento neo-adiuvante di pazienti affette da carcinoma mammario positivo al recettore per gli estrogeni: un studio clinico controllato di tipo ¿window-of-opportunity¿ mirato a verificare l¿attivit¿ del retinoide e a valutare il potenziale diagnostico di un modello di espressione genica predittivo della sensibilit¿ al farmaco

    Excerpt:
    ...Histologically confirmed non-metastatic operable primary invasive HR-positive breast cancer subjected to diagnostic core biopsy3. ...
    Trial ID:
    2018-001856-36
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    ETHAN - ET for Male BC

    Excerpt:
    ...- Breast cancer must be hormone receptor-positive and HER2-negative according to definition below assessed by local pathology....
    Trial ID:
    ETHAN
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

    Excerpt:
    ...Histologically confirmed invasive, hormone receptor-positive (ER and/or PR positive) breast cancer...
    Trial ID:
    NCT00481845
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Med Case Rep
    Title:

    Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report

    Published date:
    04/29/2021
    Excerpt:
    CONTRADICTING EVIDENCE: A 57-year old White female with hormone-receptor-positive breast...She received adjuvant endocrine therapy with anastrozole but could not tolerate this medication...she was switched to tamoxifen.
    DOI:
    10.1186/s13256-021-02792-8